VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™
September 23, 2020 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Company will host a physician symposium on AMZEEQ® and...
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
September 14, 2020 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr. Patrick...
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September
September 09, 2020 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at...
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics
September 08, 2020 08:00 ET
|
Menlo Therapeutics Inc.
Will commence trading under new Nasdaq Ticker “VYNE”, September 8, 2020 Company to ring Nasdaq Closing Bell at 4pm ET today BRIDGEWATER, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics...
Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics
September 02, 2020 08:00 ET
|
Menlo Therapeutics Inc.
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo...
Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update
August 06, 2020 07:00 ET
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6
July 28, 2020 08:00 ET
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
Menlo Therapeutics Announces Pricing of Offering of Common Stock
June 05, 2020 07:00 ET
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary...
Menlo Therapeutics Announces Proposed Offering of Common Stock
June 04, 2020 16:01 ET
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary...
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
June 02, 2020 08:00 ET
|
Menlo Therapeutics Inc.
BRIDGEWATER, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...